Renalytix PLC (RNLX)
0.641
-0.05
(-7.25%)
USD |
NASDAQ |
May 08, 16:00
0.6499
+0.01
(+1.39%)
Pre-Market: 09:10
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 32.03M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -74.36% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 12.37 |
| Price to Book Value | 12.01 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 3.140 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. |
| URL | https://www.renalytix.com |
| Investor Relations URL | https://investors.renalytixai.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Technology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Jun. 07, 2024 (est.) |
| Last Earnings Release | Feb. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. |
| URL | https://www.renalytix.com |
| Investor Relations URL | https://investors.renalytixai.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Health Care Technology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Jun. 07, 2024 (est.) |
| Last Earnings Release | Feb. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |